托珠单抗。
Tocilizumab.
机构信息
Rensselaer Polytechnic Institute, Troy, NY, USA.
出版信息
MAbs. 2009 Sep-Oct;1(5):432-8. doi: 10.4161/mabs.1.5.9497. Epub 2009 Sep 10.
Abstract
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
摘要
罗氏与中外制药合作开发托珠单抗（雅美罗），一种人源化抗白细胞介素 6 受体（IL-6R）单克隆抗体。托珠单抗在日本获批用于治疗 Castleman 病和几种类型的关节炎。在欧盟，托珠单抗获批用于治疗中重度类风湿关节炎，目前正在接受美国食品和药物管理局对该适应症的审查。托珠单抗也正在研究用于治疗其他与白细胞介素 6 相关的疾病，包括克罗恩病。
相似文献
1
Tocilizumab.托珠单抗。
MAbs. 2009 Sep-Oct;1(5):432-8. doi: 10.4161/mabs.1.5.9497. Epub 2009 Sep 10.
2
Atlizumab: anti-IL-6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai.阿特珠单抗：抗白细胞介素-6受体抗体-中外制药，抗白细胞介素-6受体抗体-中外制药，MRA-中外制药
BioDrugs. 2003;17(5):369-72. doi: 10.2165/00063030-200317050-00006.
3
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.类风湿关节炎和Castleman病患者使用抗白细胞介素-6（IL-6）受体抗体托珠单抗后血清白细胞介素-6（IL-6）和可溶性IL-6受体升高的机制及病理意义
Blood. 2008 Nov 15;112(10):3959-64. doi: 10.1182/blood-2008-05-155846. Epub 2008 Sep 10.
4
[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].[抗人白细胞介素-6受体抗体（托珠单抗，雅美罗）治疗Castleman病的新型治疗药物的药理及临床概况]
Nihon Yakurigaku Zasshi. 2005 Dec;126(6):419-25. doi: 10.1254/fpj.126.419.
5
Technology evaluation: MRA, Chugai.技术评估：磁共振血管造影（MRA），中外制药公司。
Curr Opin Mol Ther. 2003 Feb;5(1):64-9.
6
Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.抗白细胞介素-6受体抗体在炎性自身免疫性疾病中的治疗作用
Rev Recent Clin Trials. 2006 Sep;1(3):193-200. doi: 10.2174/157488706778250168.
7
[IL-6 targetting therapy for inflammatory immune diseases].[白细胞介素-6靶向治疗炎症性免疫疾病]
Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1795-800. doi: 10.2169/naika.95.1795.
8
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.抗白细胞介素-6受体抗体（托珠单抗）治疗多中心性Castleman病。
Intern Med. 2007;46(11):771-4. doi: 10.2169/internalmedicine.46.6262. Epub 2007 Jun 1.
9
Tocilizumab: a review of its use in the management of rheumatoid arthritis.托珠单抗：类风湿关节炎治疗应用综述
Drugs. 2009;69(5):609-32. doi: 10.2165/00003495-200969050-00007.
10
[IL-6 targeting therapy to retard structural joint damage in patients with rheumatoid arthritis].[靶向白细胞介素-6治疗延缓类风湿关节炎患者关节结构损伤]
Clin Calcium. 2009 Mar;19(3):425-31.
引用本文的文献
1
The impact of tocilizumab treatment on the severity of inflammation and survival rates in sepsis is significantly influence by the timing of administration.托珠单抗治疗对脓毒症炎症严重程度及生存率的影响受给药时机的显著影响。
Inflammopharmacology. 2025 Mar;33(3):1393-1405. doi: 10.1007/s10787-025-01649-6. Epub 2025 Feb 15.
2
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.托珠单抗在治疗PD-1抑制剂诱导的心肌炎性损伤及与PD-1抑制剂联合抑制肿瘤生长方面的双重疗效：一项临床前研究
Cancer Immunol Immunother. 2025 Jan 3;74(2):52. doi: 10.1007/s00262-024-03899-9.
3
A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis.托珠单抗治疗极晚发型重症肌无力的初步研究。
J Inflamm Res. 2023 Dec 8;16:5835-5843. doi: 10.2147/JIR.S423098. eCollection 2023.
4
A Review of the Occurrence of Rheumatoid Arthritis and Potential Treatments through Medicinal Plants from an Indian Perspective.从印度视角看类风湿关节炎的发生及药用植物的潜在治疗作用综述。
Curr Rheumatol Rev. 2024;20(3):241-269. doi: 10.2174/0115733971268416231116184056.
5
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.用于治疗抗肾小球基底膜病的免疫生物制剂。
Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014.
6
Characterization of HZ0412a, a novel potent humanized anti-IL-6 receptor antibody that blocks IL-6R binding to gp130.HZ0412a的特性研究，HZ0412a是一种新型强效人源化抗IL-6受体抗体，可阻断IL-6R与gp130的结合。
Antib Ther. 2023 May 11;6(2):119-126. doi: 10.1093/abt/tbad008. eCollection 2023 Apr.
7
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.嵌合抗原受体 T 细胞疗法在血液恶性肿瘤中降低毒性和提高疗效的策略。
Int J Mol Sci. 2023 May 23;24(11):9115. doi: 10.3390/ijms24119115.
8
The global landscape of approved antibody therapies.已获批抗体疗法的全球格局。
Antib Ther. 2022 Sep 6;5(4):233-257. doi: 10.1093/abt/tbac021. eCollection 2022 Oct.
9
Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.托珠单抗治疗 COVID-19 的疗效：一项伞状评价。
Rev Med Virol. 2022 Nov;32(6):e2388. doi: 10.1002/rmv.2388. Epub 2022 Aug 27.
10
A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential.一种具有抗类风湿性关节炎治疗潜力的新型人源化抗白细胞介素-6抗体HZ0408b。
Front Immunol. 2022 Jan 19;12:816646. doi: 10.3389/fimmu.2021.816646. eCollection 2021.
本文引用的文献
1
Tocilizumab.托珠单抗
Nat Rev Drug Discov. 2009 Apr;8(4):273-4. doi: 10.1038/nrd2863.
2
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.托珠单抗单药治疗与甲氨蝶呤单药治疗中重度类风湿关节炎患者的比较：AMBITION 研究。
Ann Rheum Dis. 2010 Jan;69(1):88-96. doi: 10.1136/ard.2008.105197.
3
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.抗白细胞介素-6受体单克隆抗体托珠单抗单药治疗类风湿关节炎患者的长期安全性和疗效（STREAM研究）：一项5年延长期研究的安全性和疗效证据
Ann Rheum Dis. 2009 Oct;68(10):1580-4. doi: 10.1136/ard.2008.092866. Epub 2008 Nov 19.
4
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.甲氨蝶呤反应不足的类风湿关节炎患者使用活性对照托珠单抗单药治疗的研究（SATORI）：通过IL-6受体抑制疗法显著降低疾病活动度和血清血管内皮生长因子水平
Mod Rheumatol. 2009;19(1):12-9. doi: 10.1007/s10165-008-0125-1. Epub 2008 Nov 1.
5
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.使用托珠单抗抑制白细胞介素-6受体可降低对改善病情抗风湿药物反应不足的类风湿关节炎患者的疾病活动度：托珠单抗联合传统改善病情抗风湿药物治疗研究
Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940.
6
Actemra poised to launch IL-6 inhibitors.托珠单抗准备推出白细胞介素-6抑制剂。
Nat Biotechnol. 2008 Sep;26(9):957-9. doi: 10.1038/nbt0908-957.
7
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.用托珠单抗抑制白细胞介素-6受体可改善对抗肿瘤坏死因子生物制剂难治的类风湿关节炎患者的治疗效果：一项为期24周的多中心随机安慰剂对照试验的结果
Ann Rheum Dis. 2008 Nov;67(11):1516-23. doi: 10.1136/ard.2008.092932. Epub 2008 Jul 14.
8
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.托珠单抗治疗全身型幼年特发性关节炎患者的疗效和安全性：一项随机、双盲、安慰剂对照、撤药期III期试验
Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7.
9
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.托珠单抗抑制白细胞介素-6受体对类风湿关节炎患者的影响（OPTION研究）：一项双盲、安慰剂对照的随机试验。
Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
10
What's fueling the biotech engine?是什么在推动生物技术引擎？
Nat Biotechnol. 2007 Oct;25(10):1097-104. doi: 10.1038/nbt1007-1097.
Zotero 插件